Journal articleOncotarget2016
Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic.
- Journal
- Oncotarget
- Published
- 1 June 2016
- Citations
- 23
- Type
- Article
- License
- cc by
- Full text
- Open access, reuse-licensed (cc by)
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Its licensed text is not loaded here yet, so most questions will be declined.
Try
Grants 4
- 11 Solid Tumor Therapeutics Program P30CA091842↗
- On the path to the clinic: Lead optimization and pathway analysis of the pancreatic cancer-selective drug conjugate SW … R01CA163764↗
- The Impact of Macrophage Origin on the Pathogenesis and Treatment Resistance of Pancreatic Cancer R01CA177670↗
- COMBINED TUMOR AND STROMAL TARGETING TO IMPROVE PANCREATIC CANCER RESPONSE TO IMMUNOTHERAPY R01CA203890↗